$NVLX ABRAXANE is a form of the chemotherapy drug paclitaxel (TAXOL®) that has been modified by the addition of a human protein called albumin. The combination of ABRAXANE with gemcitabine, improved overall survival in patients with metastatic pancreatic cancer by nearly two months (8.5 months vs. 6.7 months) when compared with gemcitabine alone during the phase III clinical trial. Also, Celgene's results showed that the ABRAXANE-gemcitabine combination gave a 59% increase in one-year survival rate over that seen with gemcitabine alone.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.